|
Gene: SLC25A17 |
Gene summary for SLC25A17 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC25A17 | Gene ID | 10478 |
Gene name | solute carrier family 25 member 17 | |
Gene Alias | PMP34 | |
Cytomap | 22q13.2 | |
Gene Type | protein-coding | GO ID | GO:0001561 | UniProtAcc | B4DU97 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10478 | SLC25A17 | P128T-E | Human | Esophagus | ESCC | 2.69e-34 | 8.99e-01 | 0.1241 |
10478 | SLC25A17 | P130T-E | Human | Esophagus | ESCC | 3.11e-42 | 9.63e-01 | 0.1676 |
10478 | SLC25A17 | C04 | Human | Oral cavity | OSCC | 4.53e-09 | 6.10e-01 | 0.2633 |
10478 | SLC25A17 | C21 | Human | Oral cavity | OSCC | 9.10e-24 | 8.18e-01 | 0.2678 |
10478 | SLC25A17 | C30 | Human | Oral cavity | OSCC | 2.25e-20 | 8.44e-01 | 0.3055 |
10478 | SLC25A17 | C43 | Human | Oral cavity | OSCC | 1.53e-26 | 4.58e-01 | 0.1704 |
10478 | SLC25A17 | C46 | Human | Oral cavity | OSCC | 1.15e-12 | 4.04e-01 | 0.1673 |
10478 | SLC25A17 | C51 | Human | Oral cavity | OSCC | 3.14e-03 | 3.63e-01 | 0.2674 |
10478 | SLC25A17 | C57 | Human | Oral cavity | OSCC | 4.63e-09 | 4.12e-01 | 0.1679 |
10478 | SLC25A17 | C08 | Human | Oral cavity | OSCC | 7.08e-12 | 3.21e-01 | 0.1919 |
10478 | SLC25A17 | LN22 | Human | Oral cavity | OSCC | 2.87e-03 | 5.73e-01 | 0.1733 |
10478 | SLC25A17 | LN46 | Human | Oral cavity | OSCC | 2.74e-07 | 3.30e-01 | 0.1666 |
10478 | SLC25A17 | LP15 | Human | Oral cavity | LP | 3.06e-03 | 8.04e-01 | 0.2174 |
10478 | SLC25A17 | LP17 | Human | Oral cavity | LP | 2.30e-03 | 3.99e-01 | 0.2349 |
10478 | SLC25A17 | SYSMH1 | Human | Oral cavity | OSCC | 4.07e-03 | 1.47e-01 | 0.1127 |
10478 | SLC25A17 | SYSMH2 | Human | Oral cavity | OSCC | 3.81e-05 | 1.97e-01 | 0.2326 |
10478 | SLC25A17 | SYSMH3 | Human | Oral cavity | OSCC | 1.01e-16 | 3.70e-01 | 0.2442 |
10478 | SLC25A17 | SYSMH5 | Human | Oral cavity | OSCC | 4.38e-06 | 1.52e-01 | 0.0647 |
10478 | SLC25A17 | SYSMH6 | Human | Oral cavity | OSCC | 1.80e-03 | 1.39e-01 | 0.1275 |
10478 | SLC25A17 | P1_cSCC | Human | Skin | cSCC | 3.81e-08 | 3.22e-01 | 0.0292 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
GO:00193958 | Esophagus | ESCC | fatty acid oxidation | 69/8552 | 103/18723 | 9.95e-06 | 9.44e-05 | 69 |
GO:00344407 | Esophagus | ESCC | lipid oxidation | 71/8552 | 108/18723 | 2.00e-05 | 1.74e-04 | 71 |
GO:00090628 | Esophagus | ESCC | fatty acid catabolic process | 66/8552 | 100/18723 | 3.21e-05 | 2.66e-04 | 66 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00066358 | Esophagus | ESCC | fatty acid beta-oxidation | 50/8552 | 74/18723 | 1.16e-04 | 8.04e-04 | 50 |
GO:00723297 | Esophagus | ESCC | monocarboxylic acid catabolic process | 74/8552 | 122/18723 | 6.03e-04 | 3.27e-03 | 74 |
GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:00090627 | Oral cavity | OSCC | fatty acid catabolic process | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
GO:00723296 | Oral cavity | OSCC | monocarboxylic acid catabolic process | 66/7305 | 122/18723 | 5.02e-04 | 2.95e-03 | 66 |
GO:00193957 | Oral cavity | OSCC | fatty acid oxidation | 57/7305 | 103/18723 | 5.58e-04 | 3.23e-03 | 57 |
GO:00344406 | Oral cavity | OSCC | lipid oxidation | 59/7305 | 108/18723 | 7.01e-04 | 3.89e-03 | 59 |
GO:00066357 | Oral cavity | OSCC | fatty acid beta-oxidation | 42/7305 | 74/18723 | 1.47e-03 | 7.09e-03 | 42 |
GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
GO:00442426 | Oral cavity | OSCC | cellular lipid catabolic process | 104/7305 | 214/18723 | 2.61e-03 | 1.15e-02 | 104 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
hsa041466 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
hsa0414611 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
hsa0414621 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
hsa0414631 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A17 | SNV | Missense_Mutation | c.585N>T | p.Lys195Asn | p.K195N | O43808 | protein_coding | tolerated(0.33) | benign(0.139) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC25A17 | SNV | Missense_Mutation | c.662A>G | p.Tyr221Cys | p.Y221C | O43808 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SLC25A17 | SNV | Missense_Mutation | rs371543259 | c.641N>T | p.Ala214Val | p.A214V | O43808 | protein_coding | tolerated(0.08) | possibly_damaging(0.746) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLC25A17 | SNV | Missense_Mutation | rs765118849 | c.197G>A | p.Arg66Gln | p.R66Q | O43808 | protein_coding | deleterious(0.03) | possibly_damaging(0.603) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC25A17 | SNV | Missense_Mutation | c.713N>C | p.Asn238Thr | p.N238T | O43808 | protein_coding | tolerated(0.28) | benign(0.012) | TCGA-F5-6702-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | PD | |
SLC25A17 | deletion | Frame_Shift_Del | c.84delN | p.Leu30TrpfsTer42 | p.L30Wfs*42 | O43808 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
SLC25A17 | deletion | Frame_Shift_Del | c.84delN | p.Leu30TrpfsTer42 | p.L30Wfs*42 | O43808 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
SLC25A17 | deletion | Frame_Shift_Del | c.84delN | p.Leu30TrpfsTer42 | p.L30Wfs*42 | O43808 | protein_coding | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
SLC25A17 | SNV | Missense_Mutation | novel | c.181N>T | p.Leu61Phe | p.L61F | O43808 | protein_coding | tolerated(0.32) | benign(0.022) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A17 | SNV | Missense_Mutation | rs372825776 | c.473G>A | p.Arg158His | p.R158H | O43808 | protein_coding | deleterious(0.02) | probably_damaging(0.93) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |